Differential binding of nuclear proteins to the TP53 gene promoter in male breast turnout

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1484-1487

  Nayak, B K ^a   Das, B R ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

EMSA; Male breast tumour; Nuclear proteins; P53 promoter; Southwestern

Indexed keywords

NUCLEAR PROTEIN; TRANSCRIPTION FACTOR;

ARTICLE; BINDING AFFINITY; BREAST TUMOR; ELECTROPHORETIC MOBILITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; TUMOR GROWTH;

BREAST NEOPLASMS, MALE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENES, P53; HUMANS; IMMUNOBLOTTING; MALE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS);

EID: 0030773486     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00164-0     Document Type: Article

References (30)

1. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991, 351, 453-456.
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991, 253, 49-53.
3. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54, 4855-4878.
4. Kastan MB, Zhan Q, El Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992, 71, 587-597.
5. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci, USA 1989, 86, 8763-8767.
6. Finlay CA, Hinds PW, Levine AJ. The p53 protooncogene can act as a suppressor of transformation. Cell 1989, 57, 1083-1093.
7. Miyashita T, Reed J. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293-299.
8. Ko LJ, Prives C. p53 puzzle and paradigm. Genes Dev 1996, 10, 1054-1072.
9. Skivkumar CV, Brown DR, Deb S, Deb SP. Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol 1995, 15, 6785-6793.
10. Zauberman A, Flusberg D, Haupt Y, Barak Y, Oren M. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res 1995, 23, 2584-2592.
11. Ginsberg D, Mechta F, Yaniv M, Oren M. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci, USA 1991, 88, 9979-9983.
12. Strauss BE, Shivkumar C, Dev SP, Deb S, Haas M. The MDRI downstream promoter contains sequence-specific binding sites for wild-type p53. Biochem Biophys Res Commun 1995, 188, 228-234.
13. Reisman D, Greenberg M, Rotter V. Human p53 oncogene contains one promoter upstream of exon 1 and a second, stronger promoter within intron 1. Proc Natl Acad Sci, USA 1988, 85, 5146-5150.
14. Tuck SP, Crawford L. Characterization of the human p53 gene promoter. Mol Cell Biol 1989, 9, 2163-2172.
15. Beinz-Tadmor B, Zakut-Houri R, Libresco S, Givol D, Oren M. The 5′ region of the p53 gene: evolutionary conservation and evidence for a negative regulatory element. EMBO J 1985, 4, 3209-3213.
16. Lamb P, Crawford L. Characterization of the human p53 gene. Mol Cell Biol 1986, 6, 1379-1385.
17. Deffie A, Wu H, Reinke V, Logano G. The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 1993, 13, 3415-3423.
18. Reisman D, Rotter V. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res 1993, 21, 345-350.
19. Roy B, Beamon J, Baliant E, Reisman D. Transactivation of the human p53 tumor suppressor gene by c-myc/max contributes to elevated mutant p53 expression in some tumors. Mol Cell Biol 1994, 14, 7805-7815.
20. Sun X, Shimuzu H, Yamamoto K. Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. Mol Cell Biol 1995, 15, 4489-4496.
21. Stuart ET, Haffner R, Oren M, Gruss P. Loss of p53 function through pax-mediated transcriptional repression. EMBO J 1995, 14, 5638-5645.
22. Furlong EEM, Rein T, Martin F. YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element and YY1 and E1A cooperate to amplify p53 promoter activity. Mol Cell Biol 1996, 16, 5933-5945.
23. Borring CC, Squires TS, Tong T. Cancer statistics. CA 1994, 44, 7-26.
24. Costa RH, Grayson DR, Xanthopoulos KG, Darnel JE JrJr. A liver-specific DNA-binding protein recognizes multiple nucleotide sites in regulatory regions of transthyretin, α1-antitrypsin, albumin and simian virus 40 genes. Proc Natl Acad Sci, USA 1988, 85, 3840-3844.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193, 262-268.
26. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning-A Laboratory Manual, 2nd. New York, Cold Spring Harbour Press, 1989.
27. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 1992, 70, 631-645.
28. Murasawa S, Matsubara H, Mori Y, Kijima K, Maruyama K, Inada M. Identification of a negative cis-regulatory element and trans-acting protein that inhibit transcription of the angiotensin II type I a receptor gene. J Biol Chem 1995, 270, 24282-24286.
29. Uittenbogaard MN, Giebler HA, Reisman D, Nyborg JK. Transcriptional repression of p53 by human T-cell leukemia virus type 1 tax protein. J Biol Chem 1995, 270, 28503-28506.
30. Nayak BK, Baral RN, Das BR. P53 gene mutation in relation to p53 protein accumulation in male and female breast cancer. Neoplasma 1996, 43, 305-310.